Table 1.
Patients’ main characteristics.
| Total study sample (n = 410) | ||
|---|---|---|
| N or median | % or IQR | |
| Age at diagnosis | 66 | (62-70) |
| PSA at diagnosis | 10 | (7-20) |
| Gleason at diagnosis | ||
| ≤6 (low risk) | 29 | 7.1% |
| 4+3 (intermediate risk, favorable) | 71 | 17.3% |
| 3+4 (intermediate risk, unfavorable) | 95 | 23.2% |
| ≥8 (high risk) | 215 | 52.4% |
| Hormone therapy (initial) | ||
| No | 318 | 77.6% |
| Yes | 92 | 22.4% |
| PSA post-surgery | 0.02 | (0.0-0.5) |
| Adjuvant radiotherapy | ||
| No | 312 | 76.1% |
| Yes | 98 | 23.9% |
| PSA at recurrence | 1.23 | (0.63-2.45) |
| Recurrence (% yes) | ||
| Lumbar nodes | 10 | 2.4% |
| Pelvic nodes | 89 | 21.7% |
| Bone | 49 | 12.0% |
| Lung | 1 | 0.2% |
| Prostate | 110 | 26.8% |
| No. of positive sites at PET | ||
| 0 | 176 | 42.9% |
| 1-3 | 223 | 54.4% |
| >3 | 11 | 2.7% |
| Hormone therapy (at recurrence) | ||
| No | 192 | 47.2% |
| Yes | 215 | 52.8% |
| Chemotherapy (at recurrence) | ||
| No | 380 | 93.4% |
| Yes | 27 | 6.6% |